6-9 September 2018 | Kaohsiung, Taiwan

20th Asia Pacific League of Associations for Rheumatology Congress

6-9 September 2018 | Kaohsiung, Taiwan

From Evolution to Revolution in the Treatment of RA patients

Treatment of rheumatoid arthritis (RA) has evolved from merely providing symptomatic relief to modifying disease activity in a meaningful way. During this lecture, Dr Mysler will narrate the discoveries that led to what we now call targeted synthetic disease-modifying antirheumatic drugs (DMARDs). The lecture will also review the clinical trial and real-world evidence supporting Janus kinase (JAK) inhibitors.
Methotrexate is the standard of care and first-line therapy for patients with RA but is either not tolerated or effective for the majority of patients1. Moreover, tumour necrosis factor (TNF) inhibitor monotherapy is, in general, less effective than combination therapy with methotrexate. During this lecture Dr Mysler will review the current unmet needs with the use of conventional and biologic DMARDs in RA.
The decision to discontinue methotrexate is often a patient-led decision, without physician awareness, and can be associated with suboptimal patient outcomes.2-4 Consideration of patient preferences when choosing a treatment option is important for achievement of treatment goals. The importance of shared decision-making and a treat-to-target strategy to complement the revolution of RA medications will also be emphasized.
The lecture will be followed by time for Q&A.
References
1. Weinblatt ME. Trans Am Clin Climatol Assoc. 2013;124:16-25.
2. Emery P, et al. Ann Rheum Dis. 2013;72(12):1897-1904.
3. Louder AM, et al. Am Health Drug Benefits. 2016;9(2):84-93.
4. Bliddal H, et al. Arthritis. 2015;2015:915142.
Moderator
Prof. Yi-Hsing Chen, Chief of the Division of Allergy, Immunology and Rheumatology at Taichung Veterans General Hospital, Taichung, Taiwan
Speaker
Prof. Eduardo Fabián Mysler, Director, OMI (medical research institute), Buenos Aires, Argentina